West Virginia Code of State Rules › Agency 24 - Osteopathic Medicine › Title 24 - LEGISLATIVE RULE WEST VIRGINIA BOARD OF OSTEOPATHIC MEDICINE › Series 24-02 - Osteopathic Physician Assistants › Section 24-2-2 - Definitions

Current through Register Vol. XLI, No. 28, July 12, 2024
2.1. "Active
				practice notification" means a practice notification which is currently in
				effect.
2.2. "Authorization to
				practice" means written notification from the Board that a physician assistant
				may commence practice in collaboration with physicians pursuant to an active
				practice notification.
2.3. "Board"
				means the West Virginia Board of Osteopathic Medicine.
2.4. "Collaborating Physician" means a doctor
				of osteopathic medicine, medicine, or podiatry, who is authorized to practice
				clinical medicine or podiatric medicine in West Virginia by the appropriate
				board in this state, without restriction or limitation, who collaborates with
				physician assistants.
2.5.
				"Collaboration" means overseeing the activities of the medical services
				rendered by a physician assistant. Constant physical presence of the
				collaborating physician is not required as long as the collaborating physician
				and physician assistant are, or can be, easily in contact with one another by
				telecommunication. Collaboration does not require the personal presence of the
				collaborating physician at the place or places where services are
				rendered.
2.6. "Controlled
				substances" means drugs that are classified by federal or state law in
				Schedules I, II, III, IV or V, as defined in W. Va. Code §§
									60A-2-204 through 212.
2.7. "Core duties" means medical acts that
				are included in the standard curricula of accredited physician assistant
				education programs.
2.8.
				"Endorsement" means a summer camp or volunteer endorsement to practice as a
				physician assistant under W. Va. Code §
									30-3E-1.
2.9. "Health Care Facility" means any
				licensed hospital, nursing home, extended care facility, state health or mental
				institution, clinic or physician's office.
2.10. "Hospital" means a facility licensed
				pursuant to W. Va. Code §
									16-5B-1
et
				seq
.
2.11. "License" means
				a license issued by the Board to a physician assistant applicant pursuant to
				the provisions of W. Va. Code §
									30-3E-1
et seq
.
				and the provisions of this legislative rule.
2.12. "Licensee" means a physician assistant
				licensed pursuant to the provisions of W. Va. Code §
									30-3E-1
et seq
.
				and the provisions of this legislative rule.
2.13. "Licensure" means the process of
				application to the Board and the Board's consideration and approval of
				individuals to practice as a physician assistant in collaboration with
				physicians.
2.14. "Narcotic drug"
				and "opioid" mean controlled substance medications which are natural and
				semi-synthetic derivatives of the opium poppy, as well as similar synthetic
				compounds that have analgesic or pain-relieving properties because of their
				effects in the central nervous system. Narcotic drugs and opioids include, but
				are not limited to, codeine, morphine, hydromorphone, hydrocodone, oxycodone,
				methadone, and fentanyl.
2.15.
				"NCCPA" means The National Commission on the Certification of Physician
				Assistants.
2.16. "Medical Board"
				means the West Virginia Board of Medicine.
2.17. "Physician" means a doctor of
				allopathic or osteopathic medicine who is fully licensed by this Board or the
				Board of Medicine to practice medicine or surgery in this state.
2.18. "Physician Assistant" means a person
				who meets the qualifications set forth in the Physician Assistants Practice
				Act, W. Va. Code §
									30-3E-1
et seq
.,
				and is licensed to practice medicine with a collaborating osteopathic
				physician. Physician assistant also means an individual who holds a physician
				assistant license in another state and an interstate telehealth registration
				issued by this Board.
2.19.
				"Practice notification" means a written notice to the Board that a physician
				assistant will practice in collaboration with one or more physicians in the
				state of West Virginia.
2.20.
				"Practice setting" means the type of practice environment, and includes
				hospitals, ambulatory surgical facilities, clinics, private medical offices,
				and long term care facilities.
2.21. "Prescription drug" means a drug that
				may be dispensed under federal or state law only pursuant to the prescription
				of an authorized prescriber.
2.22.
				"Prescriptive authority" means the authority of a physician assistant to
				prescribe, order, administer or dispense prescription drugs.
2.23. "Registrant" means a physician
				assistant issued an interstate telehealth registration by the Board pursuant to
				W. Va. Code §
									30-1-26.
2.24. "Registration" means an authorization
				to practice in collaboration with physicians issued by the Board pursuant to W.
				Va. Code §
									30-1-26 for the limited purpose of
				providing interstate telehealth services.
2.25. "Reporting period" means the two-year
				period preceding the renewal deadline for a license issued by the
				Board.
2.26. "Risk Assessment and
				Responsible Prescribing of Controlled Substances" means drug diversion
				training, best-practice prescribing of controlled substances training, and
				training on prescribing and administering an opioid antagonist which shall
				include all of the following components:
2.26.1. Risk Assessment and responding to
				drug diversion and drug seeking behavior, including:
2.26.1.a. Tools for conducting routine
				patient assessments for risk factors associated with drug diversion, misuse or
				abuse, and identification of substance use disorder treatment referral
				resources;
2.26.1.b. West Virginia
				specific statistics on prescription drug abuse and resulting deaths;
2.26.1.c. Identification of diversion and
				drug seeking tactics and behaviors;
2.26.1.d. Best practices for assessing,
				treating and referring patients suspected of drug seeking behavior, diversion,
				or substance use disorder;
2.26.1.e. Introduction to Medication for
				Opioid Use Disorder (MOUD) and training on the effectiveness of MOUD treatment
				including the use of full opioid agonist, partial opioid agonist, and opioid
				antagonists; and
2.26.1.f. Training
				on the impacts of stigma on treatment effectiveness including the concept of
				addiction as a chronic disease.